Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice

Science Translational Medicine

Volumn 7, Issue 275, 2015, Pages

  Fredman, Gabrielle ^a   Kamaly, Nazila ^b   Spolitu, Stefano ^a   Milton, Jaclyn ^b   Ghorpade, Devram ^a   Chiasson, Raymond ^b   Kuriakose, George ^a   Perretti, Mauro ^c   Farokzhad, Omid ^b   Tabas, Ira ^a  

^a Howard Hughes Medical Institute   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALPHA ACTIN; CHOLESTEROL; COLLAGEN TYPE 4; COLLAGENASE; FORMYLPEPTIDE RECEPTOR; INTERLEUKIN 10; LIPOCORTIN 1; LIPOPROTEIN; MACROGOL; NANOPARTICLE; POLYGLACTIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; ANNEXIN A1 PEPTIDE (2-26); LOW DENSITY LIPOPROTEIN RECEPTOR; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BODY WEIGHT; BONE MARROW CELL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; HYPERCHOLESTEROLEMIA; INFLAMMATION; LIPID DIET; MACROPHAGE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SMOOTH MUSCLE FIBER; TREATMENT OUTCOME; WESTERN DIET; ANIMAL; COMPLICATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY;

ANIMALS; ANNEXIN A1; ATHEROSCLEROSIS; COLLAGEN TYPE IV; HYPERCHOLESTEROLEMIA; MICE; MICE, KNOCKOUT; NANOPARTICLES; OXIDATIVE STRESS; PEPTIDES; RECEPTORS, LDL;

EID: 84923087134     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaa1065     Document Type: Article

References (52)

1. P. Libby, Mechanisms of acute coronary syndromes and their implications for therapy. N. Engl. J. Med. 368, 2004-2013 (2013).
2. I. Tabas, K. J. Williams, J. Boren, Subendothelial lipoprotein retention as the initiating process in atherosclerosis: Update and therapeutic implications. Circulation 116, 1832-1844 (2007).
3. C. D. Buckley, D. W. Gilroy, C. N. Serhan, Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 40, 315-327 (2014).
4. M. Perretti, F. D'Acquisto, Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat. Rev. Immunol. 9, 62-70 (2009).
5. A. J. Merched, K. Ko, K. H. Gotlinger, C. N. Serhan, L. Chan, Atherosclerosis: Evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J. 22, 3595-3606 (2008).
6. I. Tabas, Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 10, 36-46 (2010).
7. C. N. Serhan, S. D. Brain, C. D. Buckley, D. W. Gilroy, C. Haslett, L. A. O'Neill, M. Perretti, A. G. Rossi, J. L. Wallace, Resolution of inflammation: State of the art, definitions and terms. FASEB J. 21, 325-332 (2007).
8. I. Tabas, C. K. Glass, Anti-inflammatory therapy in chronic disease: Challenges and opportunities. Science 339, 166-172 (2013).
9. S. C. Smith Jr., A. Collins, R. Ferrari, D. R. Holmes Jr., S. Logstrup, D. V. McGhie, J. Ralston, R. L. Sacco, H. Stam, K. Taubert, D. A. Wood, W. A. Zoghbi, Our time: A call to save preventable death from cardiovascular disease (heart disease and stroke). Circulation 126, 2769-2775 (2012).
10. Y. Liu, D. Li, J. Chen, J. Xie, S. Bandyopadhyay, D. Zhang, A. R. Nemarkommula, H. Liu, J. L. Mehta, P. L. Hermonat, Inhibition of atherogenesis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10. Atherosclerosis 188, 19-27 (2006).
11. D. M. Mosser, X. Zhang, Interleukin-10: New perspectives on an old cytokine. Immunol. Rev. 226, 205-218 (2008).
12. H. Tilg, C. van Montfrans, A. van den Ende, A. Kaser, S. J. van Deventer, S. Schreiber, M. Gregor, O. Ludwiczek, P. Rutgeerts, C. Gasche, J. C. Koningsberger, L. Abreu, I. Kuhn, M. Cohard, A. LeBeaut, P. Grint, G. Weiss, Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon γ. Gut 50, 191-195 (2002).
13. A. Oberholzer, C. Oberholzer, L. L. Moldawer, Interleukin-10: A complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit. Care Med. 30, S58-S63 (2002).
14. H. Hasturk, A. Kantarci, T. Ohira, M. Arita, N. Ebrahimi, N. Chiang, N. A. Petasis, B. D. Levy, C. N. Serhan, T. E. Van Dyke, RvE1 protects from local inflammation and osteoclastmediated bone destruction in periodontitis. FASEB J. 20, 401-403 (2006).
15. 4 to promote the resolution of allergic airway inflammation. Nat. Immunol. 9, 873-879 (2008).
16. M. Perretti, J. Dalli, Exploiting the Annexin A1 pathway for the development of novel antiinflammatory therapeutics. Br. J. Pharmacol. 158, 936-946 (2009).
17. S. N. Cooray, T. Gobbetti, T. Montero-Melendez, S. McArthur, D. Thompson, A. J. Clark, R. J. Flower, M. Perretti, Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses. Proc. Natl. Acad. Sci. U.S.A. 110, 18232-18237 (2013).
18. M. Perretti, N. Chiang, M. La, I. M. Fierro, S. Marullo, S. J. Getting, E. Solito, C. N. Serhan, Endogenous lipid-and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat. Med. 8, 1296-1302 (2002).
19. S. Fiore, J. F. Maddox, H. D. Perez, C. N. Serhan, Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J. Exp. Med. 180, 253-260 (1994).
20. S. Krishnamoorthy, A. Recchiuti, N. Chiang, S. Yacoubian, C. H. Lee, R. Yang, N. A. Petasis, C. N. Serhan, Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc. Natl. Acad. Sci. U.S.A. 107, 1660-1665 (2010).
21. M. Perretti, A. Ahluwalia, J. G. Harris, N. J. Goulding, R. J. Flower, Lipocortin-1 fragments inhibit neutrophil accumulation and neutrophil-dependent edema in the mouse. A qualitative comparison with an anti-CD11b monoclonal antibody. J. Immunol. 151, 4306-4314 (1993).
22. N. Kamaly, G. Fredman, M. Subramanian, S. Gadde, A. Pesic, L. Cheung, Z. A. Fayad, R. Langer, I. Tabas, O. C. Farokhzad, Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Proc. Natl. Acad. Sci. U.S.A. 110, 6506-6511 (2013).
23. J. M. Chan, L. Zhang, R. Tong, D. Ghosh, W. Gao, G. Liao, K. P. Yuet, D. Gray, J. W. Rhee, J. Cheng, G. Golomb, P. Libby, R. Langer, O. C. Farokhzad, Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc. Natl. Acad. Sci. U.S.A. 107, 2213-2218 (2010).
24. R. Kalluri, Basement membranes: Structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer 3, 422-433 (2003).
25. R. Virmani, A. P. Burke, A. Farb, F. D. Kolodgie, Pathology of the unstable plaque. Prog. Cardiovasc. Dis. 44, 349-356 (2002).
26. P. Libby, Collagenases and cracks in the plaque. J. Clin. Invest. 123, 3201-3203 (2013).
27. K. J. Moore, I. Tabas, Macrophages in the pathogenesis of atherosclerosis. Cell 145, 341-355 (2011).
28. C. N. Serhan, N. Chiang, T. E. Van Dyke, Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8, 349-361 (2008).
29. X. Liao, J. C. Sluimer, Y. Wang, M. Subramanian, K. Brown, J. S. Pattison, J. Robbins, J. Martinez, I. Tabas, Macrophage autophagy plays a protective role in advanced atherosclerosis. Cell Metab. 15, 545-553 (2012).
30. Y. Wang, G. Z. Wang, P. S. Rabinovitch, I. Tabas, Macrophage mitochondrial oxidative stress promotes atherosclerosis and nuclear factor-κB-mediated inflammation in macrophages. Circ. Res. 114, 421-433 (2014).
31. 4 receptor and operative in the inflamed microvasculature. J. Immunol. 186, 4905-4914 (2011).
32. P. Libby, I. Tabas, G. Fredman, E. A. Fisher, Inflammation and its resolution as determinants of acute coronary syndromes. Circ. Res. 114, 1867-1879 (2014).
33. M. A. Gimbrone Jr., G. Garcia-Cardena, Vascular endothelium, hemodynamics, and the pathobiology of atherosclerosis. Cardiovasc. Pathol. 22, 9-15 (2013).
34. L. J. Pinderski, M. P. Fischbein, G. Subbanagounder, M. C. Fishbein, N. Kubo, H. Cheroutre, L. K. Curtiss, J. A. Berliner, W. A. Boisvert, Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes. Circ. Res. 90, 1064-1071 (2002).
35. L. E. Viiri, L. E. Full, T. J. Navin, S. Begum, A. Didangelos, N. Astola, R. K. Berge, I. Seppala, J. Shalhoub, I. J. Franklin, M. Perretti, T. Lehtimaki, A. H. Davies, R. Wait, C. Monaco, Smooth muscle cells in human atherosclerosis: Proteomic profiling reveals differences in expression of Annexin A1 and mitochondrial proteins in carotid disease. J. Mol. Cell. Cardiol. 54, 65-72 (2013).
36. Z. Mallat, A. Gojova, C. Marchiol-Fournigault, B. Esposito, C. Kamate, R. Merval, D. Fradelizi, A. Tedgui, Inhibition of transforming growth factor-β signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ. Res. 89, 930-934 (2001).
37. P. Libby, P. M. Ridker, G. K. Hansson, Progress and challenges in translating the biology of atherosclerosis. Nature 473, 317-325 (2011).
38. H. M. Peshavariya, C. J. Taylor, C. Goh, G. S. Liu, F. Jiang, E. C. Chan, G. J. Dusting, Annexin peptide Ac2-26 suppresses TNFa-induced inflammatory responses via inhibition of Rac1-dependent NADPH oxidase in human endothelial cells. PLOS One 8, e60790 (2013).
39. M. Perretti, J. D. Croxtall, S. K. Wheller, N. J. Goulding, R. Hannon, R. J. Flower, Mobilizing lipocortin 1 in adherent human leukocytes downregulates their transmigration. Nat. Med. 2, 1259-1262 (1996).
40. 4 and annexin-derived peptide-stimulated phagocytosis. FASEB J. 24, 4240-4249 (2010).
41. L. V. Norling, J. Dalli, R. J. Flower, C. N. Serhan, M. Perretti, Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: Receptor-dependent actions. Arterioscler. Thromb. Vasc. Biol. 32, 1970-1978 (2012).
42. G. Fredman, L. Ozcan, S. Spolitu, J. Hellman, M. Spite, J. Backs, I. Tabas, Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway. Proc. Natl. Acad. Sci. U.S.A. 111, 14530-14535 (2014).
43. A. J. Merched, C. N. Serhan, L. Chan, Nutrigenetic disruption of inflammation-resolution homeostasis and atherogenesis. J. Nutrigenet. Nutrigenomics 4, 12-24 (2011).
44. Z. Mallat, S. Besnard, M. Duriez, V. Deleuze, F. Emmanuel, M. F. Bureau, F. Soubrier, B. Esposito, H. Duez, C. Fievet, B. Staels, N. Duverger, D. Scherman, A. Tedgui, Protective role of interleukin-10 in atherosclerosis. Circ. Res. 85, e17-e24 (1999).
45. M. Arita, S. F. Oh, T. Chonan, S. Hong, S. Elangovan, Y. P. Sun, J. Uddin, N. A. Petasis, C. N. Serhan, Metabolic inactivation of resolvin E1 and stabilization of its anti-inflammatory actions. J. Biol. Chem. 281, 22847-22854 (2006).
46. Y. P. Sun, S. F. Oh, J.Uddin, R. Yang, K. Gotlinger, E. Campbell, S. P. Colgan, N.A. Petasis, C. N. Serhan, Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J. Biol. Chem. 282, 9323-9334 (2007).
47. N. Kamaly, Z. Xiao, P. M. Valencia, A. F. Radovic-Moreno, O. C. Farokhzad, Targeted polymeric therapeutic nanoparticles: Design, development and clinical translation. Chem. Soc. Rev. 41, 2971-3010 (2012).
48. N. Bertrand, J. Wu, X. Xu, N. Kamaly, O. C. Farokhzad, Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 66, 2-25 (2014).
49. L. Zhao, A. Seth, N. Wibowo, C. X. Zhao, N. Mitter, C. Yu, A. P. Middelberg, Nanoparticle vaccines. Vaccine 32, 327-337 (2014).
50. E. Phillips, O. Penate-Medina, P. B. Zanzonico, R. D. Carvajal, P. Mohan, Y. Ye, J. Humm, M. Gonen, H. Kalaigian, H. Schoder, H. W. Strauss, S. M. Larson, U. Wiesner, M. S. Bradbury, Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Sci. Transl. Med. 6, 260ra149 (2014).
51. M. Subramanian, E. Thorp, G. K. Hansson, I. Tabas, Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs. J. Clin. Invest. 123, 179-188 (2013).
52. T. A. Seimon, M. J. Nadolski, X. Liao, J. Magallon, M. Nguyen, N. T. Feric, M. L. Koschinsky, R. Harkewicz, J. L. Witztum, S. Tsimikas, D. Golenbock, K. J. Moore, I. Tabas, Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 12, 467-482 (2010).